HIF-2α deletion promotes Kras-driven lung tumor development

被引:108
|
作者
Mazumdar, Jolly [1 ,5 ]
Hickey, Michele M. [1 ,2 ]
Pant, Dhruv K. [1 ,3 ]
Durham, Amy C. [6 ]
Sweet-Cordero, Alejandro [7 ]
Vachani, Anil [8 ]
Jacks, Tyler [9 ]
Chodosh, Lewis A. [1 ,3 ]
Kissil, Joseph L. [10 ]
Simon, M. Celeste [1 ,4 ,5 ]
Keith, Brian [1 ,3 ]
机构
[1] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA
[5] Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA
[6] Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA
[7] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA
[8] Abramson Res Ctr, Philadelphia, PA 19104 USA
[9] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA
[10] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA
基金
美国国家卫生研究院;
关键词
hypoxia; inducible mouse model; non-small cell lung cancer; tumor suppressor; GENE-EXPRESSION; NORMAL-1; HIN-1; FREQUENT EVENT; HYPOXIA; CANCER; GROWTH; HIF-1; HYPOXIA-INDUCIBLE-FACTOR-1-ALPHA; METHYLATION; HIF-1-ALPHA;
D O I
10.1073/pnas.1001296107
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths worldwide. The oxygen-sensitive hypoxia inducible factor (HIF) transcriptional regulators HIF-1 alpha and HIF-2 alpha are overexpressed in many human NSCLCs, and constitutive HIF-2 alpha activity can promote murine lung tumor progression, suggesting that HIF proteins may be effective NSCLC therapeutic targets. To investigate the consequences of inhibiting HIF activity in lung cancers, we deleted Hif-1 alpha or Hif-2 alpha in an established Kras(G12D)-driven murine NSCLC model. Deletion of Hif-1 alpha had no obvious effect on tumor growth, whereas Hif-2 alpha deletion resulted in an unexpected increase in tumor burden that correlated with reduced expression of the candidate tumor suppressor gene Scgb3a1 (HIN-1). Here, we identify Scgb3a1 as a direct HIF-2 alpha target gene and demonstrate that HIF-2 alpha regulates Scgb3a1 expression and tumor formation in human KrasG12D-driven NSCLC cells. AKT pathway activity, reported to be repressed by Scgb3a1, was enhanced in HIF-2 alpha-deficient human NSCLC cells and xenografts. Finally, a direct correlation between HIF-2 alpha and SCGB3a1 expression was observed in approximately 70% of human NSCLC samples analyzed. These data suggest that, whereas HIF-2 alpha overexpression can contribute to NSCLC progression, therapeutic inhibition of HIF-2 alpha below a critical threshold may paradoxically promote tumor growth by reducing expression of tumor suppressor genes, including Scgb3a1.
引用
收藏
页码:14182 / 14187
页数:6
相关论文
共 50 条
  • [41] Targeting platelets for improved outcome in KRAS-driven lung adenocarcinoma
    Stephanie R. Hyslop
    Marliese Alexander
    Alesha A. Thai
    Ariena Kersbergen
    Andrew J. Kueh
    Marco J. Herold
    Jason Corbin
    Pradnya Gangatirkar
    Ashley P. Ng
    Benjamin J. Solomon
    Warren S. Alexander
    Kate D. Sutherland
    Emma C. Josefsson
    Oncogene, 2020, 39 : 5177 - 5186
  • [42] Autophagic reliance promotes metabolic reprogramming in oncogenic KRAS-driven tumorigenesis
    Lin, H. Helen
    Chung, Yiyin
    Cheng, Chun-Ting
    Ouyang, Ching
    Fu, Yong
    Kuo, Ching-Ying
    Chi, Kevin K.
    Sadeghi, Maryam
    Chu, Peiguo
    Kung, Hsing-Jien
    Li, Chien-Feng
    Limesand, Kirsten H.
    Ann, David K.
    AUTOPHAGY, 2018, 14 (09) : 1481 - 1498
  • [43] Extracellular RNA signatures of mutant KRAS-driven lung cancer
    Maroli, Sree Lakshmi Velandi
    Reggiardo, Roman E.
    Khojah, Reem
    Kim, Daniel H.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [44] Yap methylation-induced FGL1 expression suppresses anti-tumor immunity and promotes tumor progression in KRAS-driven lung adenocarcinoma
    Jiang, Ji
    Ye, Pengfei
    Sun, Ningning
    Zhu, Weihua
    Yang, Mei
    Yu, Manman
    Yu, Jingjing
    Zhang, Hui
    Gao, Zijie
    Zhang, Ningjie
    Guo, Shijie
    Ji, Yuru
    Li, Siqi
    Zhang, Cuncun
    Miao, Sainan
    Chai, Mengqi
    Liu, Wenmin
    An, Yue
    Hong, Jian
    Wei, Wei
    Zhang, Shihao
    Qiu, Huan
    CANCER COMMUNICATIONS, 2024, 44 (11) : 1350 - 1373
  • [45] Epidermal Deletion of HIF-2α Stimulates Wound Closure
    Cowburn, Andrew S.
    Alexander, Laura E. Crotty
    Southwood, Mark
    Nizet, Victor
    Chilvers, Edwin R.
    Johnson, Randall S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 (03) : 801 - 808
  • [46] Ablation of insulin receptor substrates 1 and 2 suppresses Kras-driven lung tumorigenesis
    Xu, He
    Lee, Min-Sik
    Tsai, Pei-Yun
    Adler, Ashley S.
    Curry, Natasha L.
    Challa, Saketh
    Freinkman, Elizaveta
    Hitchcock, Daniel S.
    Copps, Kyle D.
    White, Morris F.
    Bronson, Roderick T.
    Marcotrigiano, Michael
    Wu, Yaotang
    Clish, Clary B.
    Kalaany, Nada Y.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (16) : 4228 - 4233
  • [47] Targeting HIF-2α in the Tumor Microenvironment: Redefining the Role of HIF-2α for Solid Cancer Therapy
    Davis, Leah
    Recktenwald, Matthias
    Hutt, Evan
    Fuller, Schuyler
    Briggs, Madison
    Goel, Arnav
    Daringer, Nichole
    CANCERS, 2022, 14 (05)
  • [48] Toll-like receptor 2 deficiency enhances KRAS-driven lung cancer
    Liu, Chia-Hsin
    CANCER RESEARCH, 2018, 78 (13)
  • [49] A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma
    Fitzgerald, Brittany
    Connolly, Kelli A.
    Cui, Can
    Fagerberg, Eric
    Mariuzza, Dylan L.
    Hornick, Noah, I
    Foster, Gena G.
    William, Ivana
    Cheung, Julie F.
    Joshi, Nikhil S.
    CELL REPORTS METHODS, 2021, 1 (05):
  • [50] The BCL-2 family member BOK promotes KRAS-driven lung cancer progression in a p53-dependent manner
    Meinhardt, Anna-Lena
    Munkhbaatar, Enkhtsetseg
    Hockendorf, Ulrike
    Dietzen, Michelle
    Dechant, Marta
    Anton, Martina
    Jacob, Anne
    Steiger, Katja
    Weichert, Wilko
    Brcic, Luka
    McGranahan, Nicholas
    Branca, Caterina
    Kaufmann, Thomas
    Dengler, Michael A.
    Jost, Philipp J.
    ONCOGENE, 2022, 41 (09) : 1376 - 1382